Addressing the Challenges in Cancer ImagingThe Need: Addressing the Challenges in Cancer Imaging Cancer continues to be a major cause of global mortality, with over 10% of all deaths attributed to this devastating disease. Despite significant advancements in cancer research, there remains a critical need to enhance current techniques for prevention, diagnosis, imaging, therapeutics, and surgery. Existing cancer imaging methods such as computed tomography (CT) and positron emission tomography (PET) suffer from limitations in resolution and signal-to-noise ratios. Radioimmunoguided detection and surgery (RIGS) offers a promising modality for accurate mapping of cancerous tissue surfaces, but the current catalog of cancer-binding antibodies is not ideal for these applications. The Technology: Highly Stabilized 3E8 scFv The disclosed technology presents a breakthrough in cancer imaging with a highly stabilized single-chain variable antibody fragment (scFv) that specifically binds to the tumor-associated glycoprotein 72 (TAG-72). This scFv is derived from the 3E8 antibody, a humanized variant of CC49, and exhibits remarkable affinity for the sialyl-Tn epitope of TAG-72. By addressing the challenges of stabilization and affinity loss in engineered proteins, this technology overcomes the obstacles that have hindered the widespread use of such imaging agents in hospitals. Commercial Applications:
Benefits/Advantages:
In conclusion, the highly stabilized 3E8 scFv technology presents an innovative solution to the challenges faced in cancer imaging and treatment. With its remarkable binding affinity and nonimmunogenic properties, this technology opens new avenues for precise cancer detection and personalized therapeutic approaches, ultimately contributing to improved patient outcomes and a positive impact on global cancer mortality. |
Tech IDT2013-355 CollegeLicensing ManagerDahlman, Jason "Jay" InventorsCategories |